Education
About Us
Working with TipRanks
Follow Us
Thiogenesis Therapeutics Corp (TSE:TTI)
:TTI
TTI Stock Chart & Stats
C$0.56
--
Market closed
C$0.56
--
Day’s Range― - ―
52-Week RangeC$0.50 - C$0.88
Previous CloseN/A
VolumeN/A
Average Volume (3M)27.61K
Market Cap
C$29.03M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.29
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding51,835,957
10 Day Avg. Volume25,970
30 Day Avg. Volume27,615
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Thiogenesis Therapeutics Corp News
TTI FAQ
What was Thiogenesis Therapeutics Corp’s price range in the past 12 months?
Thiogenesis Therapeutics Corp lowest stock price was C$0.50 and its highest was C$0.88 in the past 12 months.
What is Thiogenesis Therapeutics Corp’s market cap?
Thiogenesis Therapeutics Corp’s market cap is C$29.03M.
When is Thiogenesis Therapeutics Corp’s upcoming earnings report date?
Thiogenesis Therapeutics Corp’s upcoming earnings report date is May 13, 2026 which is in 138 days.
How were Thiogenesis Therapeutics Corp’s earnings last quarter?
Thiogenesis Therapeutics Corp released its earnings results on Nov 26, 2025. The company reported -C$0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.05.
Is Thiogenesis Therapeutics Corp overvalued?
According to Wall Street analysts Thiogenesis Therapeutics Corp’s price is currently Overvalued.
Does Thiogenesis Therapeutics Corp pay dividends?
Thiogenesis Therapeutics Corp does not currently pay dividends.
What is Thiogenesis Therapeutics Corp’s EPS estimate?
Thiogenesis Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Thiogenesis Therapeutics Corp have?
Thiogenesis Therapeutics Corp has 51,835,957 shares outstanding.
What happened to Thiogenesis Therapeutics Corp’s price movement after its last earnings report?
Thiogenesis Therapeutics Corp reported an EPS of -C$0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Thiogenesis Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:TTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is an early stage biotech company. It is developing novel drug formulations that act as precursors to cysteamine, which is a small aminothiol compound that is endogenous in humans in small quantities.
Technical Analysis
Rapid Dose Therapeutics Corp
―
Helix BioPharma
―
PharmaTher Holdings Ltd
―
NurExone Biologic
―
Glow LifeTech
―
Options Prices
Currently, No data available
---